Press Detail

/
PRESS RELEASE

Biotest increases guidance significanty

- Increase of earnings before tax (EBT) by 41.2%

- EBIT increase by 21.6%

- Successful placement of a privately placed promissory note (Schuldschein) of EUR 210 million equivalent in the capital market

Dreieich, 12 November 2013. The Biotest Group increased sales by 13.1 % in the first nine months of 2013 compared to the same period in the previous year. In the reporting period the Group generated revenues of EUR 367.5 million compared to EUR 324.9 million in the previous year.

The Biotest Group generated revenue in the amount of USD 25 million with Bivigam(R), an immunoglobulin developed and marketed in the USA which is used to treat patients with primary humoral immune deficiencies.

Operating profit (EBIT) increased substantially by 21.6 % in the first nine months of 2013 compared to the same period in the previous year. The Biotest Group recorded EBIT of EUR 39.9 million in the period between January and September 2013 compared to EUR 32.8 million in the comparable period in 2012, which was accompanied by an increase in the EBIT margin from 10.1 % to 10.9 %. This increase was attributable to the segments Therapy and Plasma & Services. EBIT of the Therapy segment increased significantly by 21.6 % from EUR 20.4 million to EUR 24.8 million.

The financial result improved considerably in the first nine months of 2013 and amounted to EUR -3.9 million compared to EUR -7.3 million in the same period in the previous year. The writedowns recognised as part of the final sales of the Greek government bonds resulted in additional charges in 2012.

This resulted in earnings before taxes (EBT) of EUR 36.0 million for the Biotest Group. EBT is therefore 41.2 % above the comparable amount of EUR 25.5 million for the same period in the previous year. Earnings after taxes (EAT) increased significantly by 53.8 % from EUR 15.6 million to EUR 24.0 million. Altogether this resulted in earnings per share of EUR 1.96. This is equivalent to an increase of 47.4 % compared to earnings per share of EUR 1.33 for the previous year.

After the end of the reporting period, Biotest AG has successfully placed a privately placed promissory note (Schuldschein) of EUR 210 million equivalent in the capital market. Biotest offered five and seven year tranches in Euro both on fixed and floating rate basis as well as ten year tranches with a fixed
interest rate. Furthermore, investors could subscribe five-year US dollar floating rate tranches. The funds raised from the privately placed promissory note (Schuldschein) will be used for the expansion of the Dreieich site as well as for general corporate financing.

In view of the high growth of plasma proteins Biotest decided to expand production capacity as part of the 'Biotest Next Level' investment programme. The aim of the project is to double production capacity at the Dreieich location by 2018/19 and to further strengthen the international competitiveness of the Company but also to contribute to achieving the target sales figure in the amount of EUR 1 billion by the year 2020.

Outlook:
The business performance of the Biotest Group continues to be very positive. This is also confirmed by the figures for the first nine months of 2013. For this reason, the Board increases its EBIT forecast for the 2013 financial year from a so far expected increase of 10 % to 15 % to a 15 % to 20 % increase over the previous year. The Management Board reaffirms its target of increasing sales by 10 % to 15 % in the financial year 2013.

The nine-month report is available on the company's website http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm.The presentation for today's conference for analysts and journalists as well as an audio file is available for download from the website.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart